Do you want to read an article? Please log in or register.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Hepatology
Related content
COMMENTED
Inflammatory Bowel Disease
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Nutrients
Biedermann L, Doulberis M, Schreiner P, Nielsen OH, The FO, Brand S, Burk S, Hruz P, Juillerat P, Krieger-Grübel C, Leu K, Leventhal GE, Misselwitz B, Scharl S, Schoepfer A, Seibold F, Herfarth H, Rogler G
doi: 10.3390/nu16234197
Inflammatory Bowel Disease
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis
J Crohns Colitis
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
doi: 10.1093/ecco-jcc/jjaf080
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials
Clin Gastroenterol Hepatol
Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N
doi: 10.1016/j.cgh.2024.08.032
Gastrointestinal Cancer
Evaluation of the efficacy of probiotics in the chemoradiotherapy of colorectal cancer: a meta-analysis of Randomized Controlled Trials
BMC Gastroenterol
Yang R, Liu W, Cai S, Feng X, Chen Y, Cheng X, Ma J, Ma W, Tian Z, Yang W
doi: 10.1186/s12876-025-03914-y
Inflammatory Bowel Disease
The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review
Inflamm Bowel Dis
Arbabzada N, Dennett L, Meng G, Peerani F
doi: 10.1093/ibd/izae257
Further Publications
Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): a randomized controlled trial
Gastroenterology
Old O, Jankowski J, Attwood S, Stokes C, Kendall C, Rasdell C, Zimmermann A, Massa MS, Love S, Sanders S, Deidda M, Briggs A, Hapeshi J, Foy C, Moayyedi P, Barr H, BOSS Trial team
doi: 10.1053/j.gastro.2025.03.021
Further Publications
Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis
Inflamm Bowel Dis
Chhibba T, Frolkis A, Stein LR, Lee S, Schill K, Mitevska E, Judge AK, Martin ML, Martin M, Novak KL, Lu C, Ingram RJM, Chan MM, Shukla T, Seow CH, Kaplan GG, Ananthakrishnan AN, Panaccione R, Ma C
doi: 10.1093/ibd/izaf012
Gastrointestinal Cancer
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Lancet Gastroenterol Hepatol
Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC
doi: 10.1016/S2468-1253(24)00387-X
Gastrointestinal Cancer
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801
Int J Cancer
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y
doi: 10.1002/ijc.35116